RT Journal Article
SR Electronic
T1 Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.15.21258880
DO 10.1101/2021.06.15.21258880
A1 Misra, Puneet
A1 Kant, Shashi
A1 Guleria, Randeep
A1 Rai, Sanjay K
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/06/16/2021.06.15.21258880.abstract
AB Background Concern has been raised in India regarding the probable third wave of COVID-19 where children and young age group is thought to get affected the most. There is a lack of serological prevalence data in this age group. We have some interim data from our research for WHO unity protocol, which might help policymakers and the research community to answer such questions based on evidence. Hence, we conducted a study to compare the COVID -19 sero-positivity rate between children and adultsMethods/Materials This is part of an ongoing large multi-centric population-based sero-epidemiological study. The study is being conducted in five selected states with a proposed total sample size of 10,000. We have data of 4,500 participants at the time of midterm analysis from four states of India. Total serum antibody against SARS-CoV-2 virus was assessed qualitatively by using a standard ELISA kit. Here we are reporting the interim data of serological prevalence among children aged between 2 to 17 years along with a comparison with ≥18-year old participants.Results The data collection period was from 15th March 2021 to 10th June 2021. Total available data was of 4,509 participants out of which <18 years were 700 and ≥18 years was 3,809. The site-wise number of available data among the 2-17 year age group were 92, 189, 165, 146 and 108 for the site of Delhi urban resettlement colony, Delhi rural (Villages in Faridabad district under Delhi NCR), Bhubaneswar rural, Gorakhpur rural and Agartala rural area respectively. The seroprevalence was 55.7% in the <18 years age group and 63.5% in the ≥ 18 year age group. There was no statistically significant difference in prevalence between adult and children.Conclusion SARS-CoV-2 sero-positivity rate among children was high and were comparable to the adult population. Hence, it is unlikely that any future third wave by prevailing COVID-19 variant would disproportionately affect children two years or older.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a research grant (Ref No: 2020/1085497, Purchase Order: 202630166) from the WHO Country Office, New Delhi 110016, India.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical clearance from all five participating institutes (Letter No. For AIIMS, New Delhi: IEC-959/04.09.2020, AIIMS Bhubaneswar: T/EMF/CM&FM/20/44, JIPMER Puducherry: JIP/IEC/2020/248, AIIMS Gorakhpur: IHEC/AIIMS-GKP/BMR/01/22, Agartala: F.4(5-234)/AGMC/ACADEMIC/IEC MEETING). Written informed consent, assent and parental consent for participants under the legal age of giving consent was taken from all the participants as per ICMR guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesyes available with us and WHO